Urgent Call for AML Prevention: New Research Aligns with My Metabolic Approach

Groundbreaking research from Prof. George Vassiliou and Dr. Rubina Ahmed, funded by Blood Cancer UK, used data mining to show metformin can halt AML by disrupting pre-leukemic cell energy production (Nature, 2025). This resonates deeply with my metabolic strategy in How to Starve Cancer. In 2003, I faced myelodysplasia, a sneaky pre-AML condition, and used a multi-pronged approach, including berberine, a natural compound with metformin-like effects, to target cancer cell metabolism and support my recovery.

My prevention protocol now includes exogenous beta-hydroxybutyrate (BHB), a ketone body delivered via supplements like ketone esters or salts. Unlike the ketogenic diet, which Siddhartha Mukherjee’s 2023 Cancer Discovery study showed may fuel AML via acetoacetate, exogenous BHB provides a controlled dose to mimic ketosis. It starves AML cells by limiting glucose, their primary fuel, while acting as an HDAC inhibitor to reactivate tumor suppressor genes, promoting cell death. Natural NAMPT activators like PQQ and resveratrol further stress AML cells by modulating NAD+ metabolism, enhancing metformin’s and berberine’s effects.

As a proud supporter of Blood Cancer UK, I applaud their role in driving this research. But preclinical data isn’t enough—we urgently need validated clinical trials to bring these strategies to patients. Having faced myelodysplasia myself, I know the stakes. Please join me in advocating for robust research to make AML preventable. Together, we can revolutionise cancer care with metabolic therapies!

References:
Vassiliou, G., et al. (2025). Nature.

Mukherjee, S., et al. (2023). Cancer Discovery.

Xie, Z., et al. (2018). Nature Medicine.
Note: Consult a healthcare professional before starting new treatments.